These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34584567)

  • 21. Heterologous expression and purification of kynurenine-3-monooxygenase from Pseudomonas fluorescens strain 17400.
    Crozier KR; Moran GR
    Protein Expr Purif; 2007 Feb; 51(2):324-33. PubMed ID: 16973376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma.
    Sathyasaikumar KV; Pérez de la Cruz V; Pineda B; Vázquez Cervantes GI; Ramírez Ortega D; Donley DW; Severson PL; West BL; Giorgini F; Fox JH; Schwarcz R
    Antioxidants (Basel); 2022 Feb; 11(2):. PubMed ID: 35204197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
    Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
    EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback.
    Wilson K; Auer M; Binnie M; Zheng X; Pham NT; Iredale JP; Webster SP; Mole DJ
    Cell Death Dis; 2016 Apr; 7(4):e2197. PubMed ID: 27077813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
    Fujigaki H; Yamamoto Y; Saito K
    Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer.
    Liu CY; Huang TT; Chen JL; Chu PY; Lee CH; Lee HC; Lee YH; Chang YY; Yang SH; Jiang JK; Chen WS; Chao Y; Teng HW
    Front Oncol; 2021; 11():620361. PubMed ID: 33937026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surface Expression of Kynurenine 3-Monooxygenase Promotes Proliferation and Metastasis in Triple-Negative Breast Cancers.
    Lai MH; Liao CH; Tsai NM; Chang KF; Liu CC; Chiu YH; Huang KC; Lin CS
    Cancer Control; 2021; 28():10732748211009245. PubMed ID: 33887987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors.
    Smith JR; Jamie JF; Guillemin GJ
    Drug Discov Today; 2016 Feb; 21(2):315-24. PubMed ID: 26589832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition.
    Phillips RS; Iradukunda EC; Hughes T; Bowen JP
    Front Mol Biosci; 2019; 6():3. PubMed ID: 30800661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
    Johansson AS; Owe-Larsson B; Asp L; Kocki T; Adler M; Hetta J; Gardner R; Lundkvist GB; Urbanska EM; Karlsson H
    J Psychiatr Res; 2013 Nov; 47(11):1815-23. PubMed ID: 24012176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
    Winkler D; Beconi M; Toledo-Sherman LM; Prime M; Ebneth A; Dominguez C; Muñoz-Sanjuan I
    J Biomol Screen; 2013 Sep; 18(8):879-89. PubMed ID: 23690293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics.
    Maddison DC; Alfonso-Núñez M; Swaih AM; Breda C; Campesan S; Allcock N; Straatman-Iwanowska A; Kyriacou CP; Giorgini F
    PLoS Genet; 2020 Nov; 16(11):e1009129. PubMed ID: 33170836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.
    Parrott JM; O'Connor JC
    Front Psychiatry; 2015; 6():116. PubMed ID: 26347662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
    Carpenedo R; Meli E; Peruginelli F; Pellegrini-Giampietro DE; Moroni F
    J Neurochem; 2002 Sep; 82(6):1465-71. PubMed ID: 12354294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.
    Heyes MP; Chen CY; Major EO; Saito K
    Biochem J; 1997 Sep; 326 ( Pt 2)(Pt 2):351-6. PubMed ID: 9291104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
    Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing kynurenine brain levels reduces ethanol consumption in mice by inhibiting dopamine release in nucleus accumbens.
    Giménez-Gómez P; Pérez-Hernández M; Gutiérrez-López MD; Vidal R; Abuin-Martínez C; O'Shea E; Colado MI
    Neuropharmacology; 2018 Jun; 135():581-591. PubMed ID: 29705534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kynurenine Pathway as a New Target of Cognitive Impairment Induced by Lead Toxicity During the Lactation.
    Ramirez Ortega D; Ovalle Rodríguez P; Pineda B; González Esquivel DF; Ramos Chávez LA; Vázquez Cervantes GI; Roldán Roldán G; Pérez de la Cruz G; Díaz Ruiz A; Méndez Armenta M; Marcial Quino J; Gómez Manzo S; Ríos C; Pérez de la Cruz V
    Sci Rep; 2020 Feb; 10(1):3184. PubMed ID: 32081969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.